Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe)

References

• Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447–461.
   PubMed Web of Science ®Google Scholar
• SNRUBC annual reports 2011–2014. Regionala Cancercentrum i Samverkan. Nationellt kvalitetsregister för urinblåsecancer. Nationell Rapport Blåscancerregistret 2015. http://www.cancercentrum.se/vast/cancerdiagnoser/urinvagar/urinblase–och-urinvagscancer/kvalitetsregister/ [2016 Dec 5, date last accessed].
   Google Scholar
• Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41:523–531.
   PubMed Web of Science ®Google Scholar
• Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163:60–62.
   PubMed Web of Science ®Google Scholar
• Gendy R, Delprado W, Brenner P, et al. Repeat transurethral resection for non-muscleinvasive bladder cancer: a contemporary series. BJU Int. 2016; 117:54–59.
   PubMed Web of Science ®Google Scholar
• Lazica DA, Roth S, Brandt AS, et al. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int. 2014;92:131–135.
   PubMed Web of Science ®Google Scholar
• Gontero P, Gillo A, Fiorito C, et al. Prognostic factors of ‘high-grade’ Ta bladder cancers according to the WHO 2004. Classification: are these equivalent to ‘high-risk’ non-muscle-invasive bladder cancer? Urol Int. 2014;92:136–142.
   PubMed Web of Science ®Google Scholar
• Holmäng S. High-grade non-muscle-invasive bladder cancer: is re-resection necessary in all patients before intravesical bacillus Calmette-Guérin treatment? SJUN 2013;47:363–369.
   Google Scholar
• EAU guidelines on non-muscle invasive bladder cancer 2017. www.urowb.org/guidelines
   Google Scholar
• Sfakianos JP, Kim PH, Hakimi AA, et al. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol.2014;191:341–345.
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216–1223.
   PubMed Web of Science ®Google Scholar
• Jarvinen R, Kaasinen E, Sankila A, et al. Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56:260–265.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-uerin, and bacillus Calmette-Gue’ rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57:766–773.
   PubMed Web of Science ®Google Scholar
• Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682–686. discussion 686–7.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden A, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970.
   PubMed Web of Science ®Google Scholar
• Divrik RT, Yildirim U, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175:1641–1644.
   PubMed Web of Science ®Google Scholar
• Patschan O, Holmäng S, Hosseini A, et al. Secondlook resection for primary stage T1 bladder cancer: a population-based study. Scand J Urol. 2017;51:301–307.
   PubMed Web of Science ®Google Scholar
• Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer. A population-based analysis. Cancer 2013;119:3219–3227.
   PubMed Web of Science ®Google Scholar
• Haggstrom C, Liedberg F, Hagberg O, et al. Cohort profile: the Swedish National Register of Urinary Bladder Cancer [SNRUBC] and the bladder cancer data base Sweden [BladderBaSe]. BMJ Open. 2017;7:e016606.
   PubMed Web of Science ®Google Scholar
• Thorstenson A, Hagberg O, Ljungberg B, et al. Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. Scand J Urol. 2016;22:1–6.
   Google Scholar
• Sjöström C, Thorstenson A, Ströck V, et al. Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. Scand J Urol. 2018;52:186–193.
   PubMed Web of Science ®Google Scholar
• Spencer BA, McBride RB, Hershman DL, et al. Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non–muscle-invasive bladder cancer. J Oncol Practice 2012;9:92–98. published online ahead of print at jop.ascopubs.org on October 30, 2012.
   PubMedGoogle Scholar
• Goodwin JS, Hunt WC, Key CR, et al. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA 1987;258:3125–3130.
   PubMed Web of Science ®Google Scholar
• Gore J, Kwan L, Saigal C, et al. Marriage and mortality in bladder carcinoma. Cancer 2005;104:1188–1194.
   PubMed Web of Science ®Google Scholar
• Datta GD, Neville BA, Kawachi I, et al. Marital status and survival following bladder cancer. J Epidemiol Community Health.2009;63:807–813.
   PubMed Web of Science ®Google Scholar
• Merrill RM, Johnson E. Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA. J Cancer Surviv. 2017;11:578–589.
   PubMed Web of Science ®Google Scholar
• Gróf M, Vagašová T, Oltman M, et al. Inequalities in cancer deaths by age gender and education. Cent Eur J Public Health. 2017;25:59–63.
   Web of Science ®Google Scholar
• Liedberg F, Hagberg O, Holmäng S, et al. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol. 2015;49:290–295.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro L, Portillo JA, Fernandez JM, et al. Maintenance therapy with 3-monthly bacillus Calmette-Guérin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol. 2015;68:256–262.
   PubMed Web of Science ®Google Scholar
• van Rhijn BWG, Burger M. Low adherence to guidelines in non-muscle-invasive disease. Nat Rev Urol. 2016;13:570–571.
   PubMed Web of Science ®Google Scholar